Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs for virology and immunology indications. Its pipeline includes EDP-514, a phase 1b candidate for chronic hepatitis B virus (HBV) infection; zelicapavir and EDP-323, both in phase II for respiratory syncytial virus (RSV); EDP-235, in phase II for human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); and EPS-3903 for atopic dermatitis. The company also has a collaboration with Abbott Laboratories to develop and commercialize HCV protease inhibitors such as paritaprevir and glecaprevir. Enanta's work primarily targets viral infections and immune-related conditions, leveraging its expertise in small molecule drug discovery.

Enanta Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ENTA. The trading currency for its shares is the US Dollar (USD). As a US-based company, its stock is traded in the primary currency of the United States, making it accessible to investors through major US brokerages. The NasdaqGS is a highly regulated exchange that lists many biotechnology and technology companies, providing liquidity and visibility for Enanta's shares.

Enanta Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing drugs that address unmet medical needs, particularly in virology and immunology. The biotechnology industry is characterized by high research and development costs, long product development cycles, and significant regulatory oversight. Enanta's work in developing small molecule drugs for diseases like hepatitis B, respiratory syncytial virus, and coronaviruses places it firmly within this innovative and high-risk sector.

Enanta Pharmaceuticals is headquartered in Watertown, Massachusetts, United States. The company was incorporated in 1995, giving it over two decades of experience in drug discovery and development. Watertown is part of the greater Boston area, a major hub for biotechnology and pharmaceutical research, providing access to a skilled workforce and research institutions. The company's long history since the mid-1990s reflects its sustained commitment to developing therapies for viral infections and immune disorders, with a pipeline that has evolved to include candidates for HBV, RSV, coronaviruses, and inflammatory conditions.

Enanta Pharmaceuticals' pipeline includes several notable drug candidates and a key collaboration. Its most advanced programs target respiratory syncytial virus (RSV) with zelicapavir and EDP-323 in phase II, and human coronaviruses with EDP-235 also in phase II. For hepatitis B, EDP-514 is in phase 1b. Additionally, the company is developing EDP-978 for chronic spontaneous urticaria and EPS-3903 for atopic dermatitis. Enanta has a collaborative development and license agreement with Abbott Laboratories to develop and commercialize HCV NS3 and NS3/4A protease inhibitors, including paritaprevir and glecaprevir, which have been important in hepatitis C treatment. This partnership highlights Enanta's ability to leverage its expertise through strategic alliances.